KPTI

Selinexor, XPOVIO (Severe COVID )

COVID-19 Therapy

Stage (next event)

Expected Date

Phase 2 (Data at ISIRV-AVG )

TBD

Catalyst Info & Data Links

TITLE: Selinexor, XPOVIO for Severe COVD-19 - Phase 2

  • ClinicalTrial.gov (NCT04349098): Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (Coronavirus)


WHAT IS THE NEXT CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA/EVENTS


MECHANISM OF ACTION/RATIONALE

  • Nuclear export inhibitor

  • Inhibits XPO1 (see slide 5), which is believed to impact tumor cells in 3 ways

1. Increases nuclear levels and activation of tumor suppressor proteins
2. Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels
3. Retains activated glucocorticoid receptor in the nucleus

MARKET

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon